Gabelli Funds Portfolio Manager Jeff Jonas in CNBC Pro

These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat.

What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In a best case scenario, these experimental drugs would not only protect against muscle loss, they could also speed up fat loss when taken alongside what are called incretin therapies, such as Ozempic and Mounjaro.

Read more here: